Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
作者信息
Schifrin L G
出版信息
Int J Health Serv. 1974 Winter;4(1):147-55. doi: 10.2190/DCU8-7F68-E48J-4ER5.
PMID:4829893
Abstract
摘要
相似文献
1
Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
Int J Health Serv. 1974 Winter;4(1):147-55. doi: 10.2190/DCU8-7F68-E48J-4ER5.
2
The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.美国食品药品监督管理局的药品监管体系：对现行安全性和有效性要求的辩护
Int J Health Serv. 1974 Winter;4(1):95-107. doi: 10.2190/TW4Q-WEDA-2Q7V-RHAH.
3
The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?品牌药与仿制药之争：制药行业中是否存在生产质量更高药品的细分领域？
Contemp Pharm Pract. 1982 Spring;5(2):130-5.
4
A perspective on US drug reimportation.对美国药品再进口的一种观点。
JAMA. 2005 Jan 19;293(3):358-62. doi: 10.1001/jama.293.3.358.
5
QUAD routes out inferior drugs.四方查处劣质药品。
Can Hosp. 1973 May;50(5):58-9.
6
The 1941 sulfathiazole disaster and the birth of good manufacturing practices.1941年磺胺噻唑灾难与良好生产规范的诞生
Pharm Hist. 1999;41(1):16-25.
7
The economic wisdom of regulating pharmaceutical "freebies".
Duke Law J. 1991 Feb(1):206-39.
8
Pharmaceutical Greed and Its Consequences.制药行业的贪婪及其后果。
Conn Med. 2016 May;80(5):315-6.
9
FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.美国食品药品监督管理局认可将第一世界国家的药品监管机构作为缓解美国药品短缺的一种方式。
Am J Health Syst Pharm. 2012 Oct 1;69(19):1626, 1628. doi: 10.2146/ajhp120478.
10
Physician-ownership in pharmacies and drug repackagers.
Inquiry. 1975 Mar;12(1):26-36.
Zotero 插件